Roche has more than five weight-loss companion medicines, CEO says
The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and Co.
Eli Lilly and Co.
Articles
Weight-loss drugs are supposed to be forever … until they run out
Recurrent shortages, shifting insurance coverage, indecision and a lack of guidance about side effects and dosing have led to challenges for some patients prescribed Mounjaro, Ozempic, Zepbound or Wegovy.
Lilly seeks court ruling that could mean big money for new weight-loss drug
The Indianapolis-based drugmaker filed a suit in federal court this month, challenging the U.S. Food and Drug Administration’s ruling that the company’s experimental obesity treatment not a biological product.
Eli Lilly requests records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell the compounded versions has intensified.
Lilly to make $1.8B investment in two Ireland manufacturing facilities
The expansion projects will boost production of medicines for Alzheimer’s disease, diabetes and obesity.
Lilly names new chief financial officer
Lucas Montarce, who has been with Lilly since 2001 and most recently served as president for its Spain, Portugal and Greece operations, is now the company’s CFO and executive vice president.
Eli Lilly ramps up fight against imitation weight-loss drugs
Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent.
Olympians Biles, Thomas continue Indy trip with visit to Lilly
After taking in the Indiana Fever’s victory on Wednesday, Simone Biles and Gabby Thomas discussed teamwork on Thursday with thousands of employees for Team USA sponsor Eli Lilly and Co.
Lilly now selling vials of blockbuster Zepbound at 50% discount
Lilly said its new option will help millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage, and those who need to self-pay outside of insurance.
Study: Lilly’s Zepbound cut risk of diabetes by 94% in obese people
The longest continuous study of Indianapolis-based Lilly’s drug Zepbound to date included more than 1,000 patients.
Lilly opens new 12-story, $700M R&D center in Boston
Lilly is moving about 200 scientists and researchers who had worked in nearby Cambridge, Massachusetts, to the new center, and plans to add about 300 employees.
Purdue, Lilly establish medical-focused research center
The Eli Lilly and Co. and Purdue University Research Alliance Center involves more than 50 researchers and 65 graduate students.
Eli Lilly taps blue-chip bond market to fund Morphic acquisition
Lilly is buying Morphic for $3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.
Strong sales of Mounjaro, Zepbound push Lilly profit up 68%
The Indianapolis-based drugmaker said revenue increased 36% in the quarter, to $11.3 billion. Zepbound, the popular obesity drug that launched in December, crossed into blockbuster territory, with sales of $1.23 billion in the quarter.
Lilly CEO says weight-loss drug shortage to end ‘very soon’
Meanwhile, Lilly announced that Zepbound improved the long-term health of patients with obesity-related heart failure in a study.
Blood tests for Alzheimer’s might be coming to your doctor’s office.
Researchers reported Sunday that new blood tests were 91% accurate in detecting Alzheimer’s disease, far more accurate than a diagnosis from primary care doctors and specialists.
Lilly inches toward rare $1 trillion market-value distinction
The spotlight is turning to Indianapolis-based Eli Lilly and Co. as the next possible member of the so-called “Trillion-Dollar Club,” based on the drugmaker’s climbing stock price and swelling demand for its treatments for diabetes, obesity and other diseases.
How Lilly wooed Massachusetts biotech with flurry of offers
It was a mating dance that lasted more than three years. At the end, Eli Lilly and Co. wound up buying a Massachusetts-based biotech developing treatments for inflammatory bowel disease for $3.2 billion.
Hims & Hers adds longtime Novo executive to board amid weight-loss bet
Shortages of brand-name drugs made by Novo and Eli Lilly and Co. have allowed pharmacies to make what are essentially copies, and telehealth companies like Hims are selling them to patients at a steep discount.
Lilly shares slide 7% after Roche announces obesity pill test results
The Roche drug is a once-daily pill, compared to Lilly’s tirzepatide, sold under the brand names Mounjaro (for diabetes) and Zepbound (for obesity), which is a once-weekly shot.